tiprankstipranks
Trending News
More News >
Advertisement

VNGLF - ETF AI Analysis

Compare

Top Page

VNGLF

Vanguard FTSE Developed Europe UCITS ETF Accum EUR (VNGLF)

Rating:62Neutral
Price Target:
VNGLF, the Vanguard FTSE Developed Europe UCITS ETF Accum EUR, has a solid overall rating driven mainly by high-quality European blue chips like HSBC, Novartis, and AstraZeneca, which show strong financial performance, positive earnings outlooks, and generally supportive valuations. Additional support comes from stable, well-established names such as Nestlé and Siemens, though some holdings like SAP and Shell face technical or growth challenges that slightly weigh on the fund’s appeal. The main risk is its concentration in developed European markets, which makes the ETF sensitive to regional economic and regulatory conditions.
Positive Factors
Broad European Diversification
The fund spreads its investments across many developed European countries, which helps reduce the impact of problems in any single market.
Low Expense Ratio
The ETF charges a very low ongoing fee, so more of the fund’s returns stay in investors’ pockets over time.
Solid Recent Performance
The ETF has shown steady gains over the past month, three months, and year-to-date, indicating generally supportive market conditions for its holdings.
Negative Factors
Heavy Tilt to Financials and Industrials
A large share of the portfolio is in financial and industrial companies, which can hurt returns if these sectors face a downturn.
Mixed Performance Among Top Holdings
While some major positions have performed strongly, several other large holdings have been weak this year, which can drag on overall results.
Limited Exposure Beyond Developed Europe
The ETF is focused mainly on developed European markets with only a small allocation to the U.S., offering little exposure to faster-growing regions elsewhere.

VNGLF vs. SPDR S&P 500 ETF (SPY)

VNGLF Summary

This ETF, the Vanguard FTSE Developed Europe UCITS ETF, aims to track the FTSE Developed Europe Index, which covers many major companies across developed European countries like the UK, France, and Germany. It holds well-known names such as Nestlé, Shell, and AstraZeneca, and spreads your money across many sectors including financials, industrials, and health care. Someone might invest in this fund to get broad, low-cost diversification in European stocks and to benefit from reinvested dividends for long-term growth. A key risk is that its value can rise and fall with the European stock market.
How much will it cost me?The Vanguard FTSE Developed Europe UCITS ETF (VNGLF) has an expense ratio of 0.1%, meaning you’ll pay $1 per year for every $1,000 invested. This is lower than average because the fund is passively managed, tracking the FTSE Developed Europe Index to keep costs down.
What would affect this ETF?Positive drivers for VNGLF include potential economic growth in developed European countries like Germany, France, and the UK, which could boost the performance of its top holdings in sectors such as financials, healthcare, and technology. However, negative factors such as rising interest rates or geopolitical tensions in Europe could impact market stability and weigh on the ETF's performance. Additionally, sector-specific challenges, like regulatory changes in healthcare or energy, could affect the fund's returns.

VNGLF Top 10 Holdings

This Vanguard Europe ETF leans heavily on healthcare and consumer giants, with Roche, Novartis, and AstraZeneca doing much of the heavy lifting as their shares keep rising on solid drug pipelines and steady cash flows. Nestlé adds a defensive backbone, quietly grinding higher, while HSBC benefits from a firmer banking backdrop. On the flip side, SAP and LVMH have been losing steam lately, acting as mild brakes on performance. ASML’s strong run underscores a tech undercurrent, but overall the fund stays broadly diversified across developed European markets rather than any single country or sector.
Name
Company Name
Weight %
Market Value
Market Cap
Yearly Gain
Overall Rating
ASML Holding NV3.85%$256.67M€450.59B80.13%
76
Outperform
Roche Holding AG2.16%$144.30MCHF256.31B21.75%
73
Outperform
HSBC Holdings2.05%$136.56M£202.74B35.68%
80
Outperform
Novartis AG1.93%$128.84MCHF230.97B25.96%
80
Outperform
AstraZeneca1.89%$126.13M$295.60B19.89%
80
Outperform
Nestlé SA1.63%$108.78MCHF204.54B-0.11%
71
Outperform
Siemens1.51%$100.96M€167.96B-4.39%
74
Outperform
Shell (UK)1.50%$99.97M£189.65B27.87%
73
Outperform
SAP SE1.41%$94.07M€189.51B-30.51%
66
Neutral
Banco Santander1.28%$85.74M€139.93B57.31%
73
Outperform

VNGLF Technical Analysis

Technical Analysis Sentiment
Negative
Last Price
Price Trends
50DMA
65.66
Negative
100DMA
63.32
Negative
200DMA
60.72
Positive
Market Momentum
MACD
-0.87
Positive
RSI
35.91
Neutral
STOCH
23.62
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For VNGLF, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 65.74, equal to the 50-day MA of 65.66, and equal to the 200-day MA of 60.72, indicating a neutral trend. The MACD of -0.87 indicates Positive momentum. The RSI at 35.91 is Neutral, neither overbought nor oversold. The STOCH value of 23.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VNGLF.

VNGLF Peer Comparison

Comparison Results
Name
Price
Price Target
AUM
Expense Ratio
Overall Rating
$2.30B0.10%
62
Neutral
$9.37B0.50%
63
Neutral
$8.63B0.09%
65
Neutral
$8.47B0.09%
64
Neutral
$4.78B0.29%
68
Neutral
$1.75B0.58%
60
Neutral
Performance Comparison
Ticker
Company Name
Price
Change
% Change
VNGLF
Vanguard FTSE Developed Europe UCITS ETF Accum EUR
63.06
9.26
17.21%
EZU
iShares MSCI Eurozone ETF
BBEU
JPMorgan BetaBuilders Europe ETF
IEUR
iShares Core MSCI Europe ETF
FEZ
SPDR EURO STOXX 50 ETF
HEDJ
WisdomTree Europe Hedged Equity Fund
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents
Advertisement